Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1646
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18307309 | METHODS FOR SELECTING PATIENTS FOR TREATMENT WITH AN NGF ANTAGONIST | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17602562 | HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18306958 | MULTISPECIFIC ANTIBODIES TARGETING IL-13 AND IL-18 | Non-Final OA | NOVARTIS AG |
| 17421337 | EX VIVO ACTIVATED T-LYMPHOCYTIC COMPOSITIONS AND METHODS OF USING THE SAME | Non-Final OA | CHILDREN'S NATIONAL MEDICAL CENTER |
| 18020584 | SINGLE VARIABLE DOMAIN AND ANTIGEN BINDING MOLECULE BINDING BCMA | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18318425 | EFFECTIVE DOSAGE OF RECOMBINANT SERPIN-FC FUSION PROTEIN FOR USE IN A METHOD OF TREATING AAT DEFICIENCY IN A SUBJECT | Non-Final OA | Sanofi AATD Inc. |
| 17758116 | BCMA-DIRECTED CELLULAR IMMUNOTHERAPY COMPOSITIONS AND METHODS | Non-Final OA | Nkarta, Inc. |
| 17428341 | STABILIZED Fc FUSION PROTEIN SOLUTIONS | Non-Final OA | ARECOR LIMITED |
| 17796148 | METHODS AND COMPOSITIONS FOR TREATING CANCER OR VIRAL INFECTION WITH A PLA2G2D ANTAGONIST | Final Rejection | Apeximmune Therapeutics Inc. |
| 17758524 | TGF-BETA INHIBITORS AND USE THEREOF | Non-Final OA | SCHOLAR ROCK, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy